Cite
HARVARD Citation
Kolberg, H. et al. (n.d.). Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications. European journal of cancer. pp. S103-S104. [Online].